Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance
Abstract
Exercise intolerance is a clinical hallmark of heart failure with preserved ejection fraction (HFpEF) that confers high morbidity and predicts mortality. The mechanisms underlying exercise intolerance in HFpEF are diverse and often include compound deficits in multi-organ reserve capacity that culminate in marked functional limitations. This review describes aetiologies of exercise intolerance in HFpEF, tools to quantify relative physiologic deficits unmasked during exercise, and insights gained from interventional trials that have aimed to augment exercise capacity in HFpEF. The domain-based phenotyping approach described highlights the value of comprehensive phenotyping of both cardiac and extra-cardiac reserve capacity to advance understanding of how to deploy individualized interventions to bolster exercise tolerance in HFpEF.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.